NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Revance Therapeutics, Inc. (NASDAQ:RVNC) common stock in its June 19, 2014 follow-on public stock offering (the “Offering”). The lawsuit seeks to recover damages for Revance Therapeutics investors under the federal securities laws.
To join the Revance Therapeutics class action, go to the firm’s website at http://www.rosenlegal.com/cases-634.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The lawsuit alleges that the Registration Statement issued in connection with the Offering failed to disclose, among other things, that: (i) Revance Therapeutics had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; (ii) Revance Therapeutics did not have the quality or quantity of RT001 on hand sufficient to complete and successful Phase 3 clinical trial. When the true details entered the market, Revance Therapeutics’ share price declined and investors suffered damages.
If you wish to join the class action and recover your losses, go to the firm’s website http://www.rosenlegal.com/cases-634.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
